Orexigen said it reached a tentative agreement with the FDA to conduct a two-year trial on the heart safety of its pipeline drug Contrave.
Mainly due to safety concerns, the FDA has not approved a new prescription weight loss pill in more than a decade.
Related Articles on Obesity:
Diabetes Group: Bariatric Surgery Fights Type 2 Diabetes in Obese Patients
Half of Americans Expected to be Obese by 2030
Report: Obesity Rates Continued to Rise Last Year
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
